(-)-Epicatechin reduces blood pressure increase in high-fructose-fed rats: Effects on the determinants of nitric oxide bioavailability

Journal of Nutritional Biochemistry

Volumn 26, Issue 7, 2015, Pages 745-751

  Litterio, Maria C ^a   Vazquez Prieto, Marcela A ^b   Adamo, Ana M ^a   Elesgaray, Rosana ^a   Oteiza, Patricia I ^c   Galleano, Monica ^a   Fraga, Cesar G ^a,c  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b UNIVERSIDAD NACIONAL DE CUYO   (Argentina)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Flavonoids; Fructose; Hypertension; Metabolic syndrome; Oxidants; Superoxide anion

Indexed keywords

EPICATECHIN; FRUCTOSE; MITOGEN ACTIVATED PROTEIN KINASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; STRESS ACTIVATED PROTEIN KINASE; SUPEROXIDE; ANTIHYPERTENSIVE AGENT; ANTIOXIDANT; CARBOHYDRATE DIET; CATECHIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; NEUTROPHIL CYTOSOLIC FACTOR 1; NOS3 PROTEIN, RAT; NOX4 PROTEIN, RAT; P22-PHOX PROTEIN, RAT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AORTA; ARTICLE; BLOOD PRESSURE; CARBOHYDRATE DIET; CONTROLLED STUDY; DIET SUPPLEMENTATION; ENZYME ACTIVITY; NONHUMAN; PROTEIN EXPRESSION; RAT; ADVERSE EFFECTS; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DIETARY SUPPLEMENT; ENZYMOLOGY; HYPERTENSION; MALE; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PROTEIN PROCESSING; RANDOMIZATION; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT; THORACIC AORTA; VASCULAR ENDOTHELIUM;

ANIMALS; ANTIHYPERTENSIVE AGENTS; ANTIOXIDANTS; AORTA, THORACIC; CATECHIN; DIETARY CARBOHYDRATES; DIETARY SUPPLEMENTS; ENDOTHELIUM, VASCULAR; FRUCTOSE; HYPERTENSION; MALE; MAP KINASE SIGNALING SYSTEM; NADPH OXIDASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; RANDOM ALLOCATION; RATS, SPRAGUE-DAWLEY; SUPEROXIDES;

EID: 84942983825     PISSN: 09552863     EISSN: 18734847     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2015.02.004     Document Type: Article

References (58)

1. Ervin RB. Prevalence of metabolic syndrome among adults 20 years of age and over, by sex, age, race and ethnicity, and body mass index: United States 2003-2006. Natl Health Stat Rep 2009;5:1-7.
2. Lteif AA, Han K, Mather KJ. Obesity, insulin resistance, and the metabolic syndrome: determinants of endothelial dysfunction in whites and blacks. Circulation 2005;112: 32-8.
3. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 2000;87:840-4.
4. Govers R, Rabelink TJ. Cellular regulation of endothelial nitric oxide synthase. Am J Physiol Renal Physiol 2001;280:F193-206.
5. Forstermann U, Closs EI, Pollock JS, Nakane M, Schwarz P, Gath I, et al. Nitric oxide synthase isozymes. Characterization, purification, molecular cloning, and functions. Hypertension 1994;23:1121-31.
6. Griendling KK, FitzGerald GA. Oxidative stress and cardiovascular injury: part I: basic mechanisms and in vivo monitoring of ROS. Circulation 2003;108:1912-6.
7. Forstermann U, Munzel T. Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation 2006;113:1708-14.
8. Goldstein S, Czapski G. The reaction of NO. with O2.-and HO2.: a pulse radiolysis study. Free Radic Biol Med 1995;19:505-10.
9. Mount PF, Power DA. Nitric oxide in the kidney: functions and regulation of synthesis. Acta Physiol (Oxf) 2006;187:433-46.
10. Paravicini TM, Touyz RM. NADPH oxidases, reactive oxygen species, and hypertension: clinical implications and therapeutic possibilities. Diabetes Care 2008;31(Suppl 2):S170-80.
11. Pendyala S, Usatyuk PV, Gorshkova IA, Garcia JG, Natarajan V. Regulation of NADPH oxidase in vascular endothelium: the role of phospholipases, protein kinases, and cytoskeletal proteins. Antioxid Redox Signal 2009;11:841-60.
12. Drummond GR, Selemidis S, Griendling KK, Sobey CG. Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets. Nat Rev Drug Discov 2011;10:453-71.
13. Csanyi G, Taylor WR, Pagano PJ. NOX and inflammation in the vascular adventitia. Free Radic Biol Med 2009;47:1254-66.
14. Crozier A, Jaganath IB, Clifford MN. Dietary phenolics: chemistry, bioavailability and effects on health. Nat Prod Rep 2009;26:1001-43. [15] Galleano M, Calabro V, Prince PD, Litterio MC, Piotrkowski B, Vazquez-Prieto MA, et al. Flavonoids and metabolic syndrome. Ann N Y Acad Sci 2012;1259:87-94.
15. Galleano M, Calabro V, Prince PD, Litterio MC, Piotrkowski B, Vazquez-Prieto MA, et al. Flavonoids and metabolic syndrome. Ann N Y Acad Sci 2012;1259:87-94
16. Alam MA, Subhan N, Rahman MM, Uddin SJ, Reza HM, Sarker SD. Effect of citrus flavonoids, naringin and naringenin, on metabolic syndrome and their mechanisms of action. Adv Nutr 2014;5:404-17.
17. Almoosawi S, Fyfe L, Ho C, Al-Dujaili E. The effect of polyphenol-rich dark chocolate on fasting capillary whole blood glucose, total cholesterol, blood pressure and glucocorticoids in healthy overweight and obese subjects. Br J Nutr 2010;103:842-50.
18. Davison K, Coates AM, Buckley JD, Howe PR. Effect of cocoa flavanols and exercise on cardiometabolic risk factors in overweight and obese subjects. Int J Obes (Lond) 2008;32:1289-96.
19. Grassi D, Desideri G, Necozione S, Lippi C, Casale R, Properzi G, et al. Blood pressure is reduced and insulin sensitivity increased in glucose-intolerant, hypertensive subjects after 15 days of consuming high-polyphenol dark chocolate. J Nutr 2008;138:1671-6.
20. Schroeter H, Heiss C, Balzer J, Kleinbongard P, Keen CL, Hollenberg NK, et al. (-)-Epicatechin mediates beneficial effects of flavanol-rich cocoa on vascular function in humans. Proc Natl Acad Sci U S A 2006;103:1024-9.
21. Fraga CG, Litterio MC, Prince PD, Calabro V, Piotrkowski B, Galleano M. Cocoa flavanols: effects on vascular nitric oxide and blood pressure. J Clin Biochem Nutr 2011;48:63-7.
22. Litterio MC, Jaggers G, Sagdicoglu Celep G, Adamo AM, Costa MA, Oteiza PI, et al. Blood pressure-lowering effect of dietary (-)-epicatechin administration in LNAME-treated rats is associated with restored nitric oxide levels. Free Radic Biol Med 2012;53:1894-902.
23. Galleano M, Bernatova I, Puzserova A, Balis P, Sestakova N, Pechanova O, et al. (-)-Epicatechin reduces blood pressure and improves vasorelaxation in spontaneously hypertensive rats by NO-mediated mechanism. IUBMB Life 2013;65:710-5.
24. Gomez-Guzman M, Jimenez R, Sanchez M, Romero M, O'Valle F, Lopez-Sepulveda R, et al. Chronic (-)-epicatechin improves vascular oxidative and inflammatory status but not hypertension in chronic nitric oxide-deficient rats. Br J Nutr 2011; 106:1337-48.
25. Gomez-Guzman M, Jimenez R, Sanchez M, Zarzuelo MJ, Galindo P, Quintela AM, et al. Epicatechin lowers blood pressure, restores endothelial function, and decreases oxidative stress and endothelin-1 and NADPH oxidase activity in DOCAsalt hypertension. Free Radic Biol Med 2012;52:70-9.
26. Bettaieb A, Vazquez Prieto MA, Rodriguez Lanzi C, Miatello RM, Haj FG, Fraga CG, et al. (-)-Epicatechin mitigates high-fructose-associated insulin resistance by modulating redox signaling and endoplasmic reticulum stress. Free Radic Biol Med 2014;72:247-56.
27. Xiong X, You C, Feng QC, Yin T, Chen ZB, Ball P, et al. Pulse width modulation electroacupuncture on cardiovascularremodelingandplasmanitric oxideinspontaneously hypertensive rats. Evid Based Complement Alternat Med 2011;2011:812160. http://dx.doi.org/10.1093/ecam/neq063.
28. Costa MA, Loria A, Elesgaray R, Balaszczuk AM, Arranz C. Role of nitric oxide pathway in hypotensive and renal effects of furosemide during extracellular volume expansion. J Hypertens 2004;22:1561-9.
29. Li JM, Wheatcroft S, Fan LM, Kearney MT, Shah AM. Opposing roles of p47phox in basal versus angiotensin II-stimulated alterations in vascular O2-production, vascular tone, and mitogen-activated protein kinase activation. Circulation 2004; 109:1307-13.
30. Oberhammer F, Fritsch G, Schmied M, Pavelka M, Printz D, Purchio T, et al. Condensation of the chromatin at the membrane of an apoptotic nucleus is not associated with activation of an endonuclease. J Cell Sci 1993;104(Pt 2):317-26.
31. Zakula Z, Koricanac G, Tepavcevic S, Stojiljkovic M, Milosavljevic T, Isenovic ER. Impairment of cardiac insulin signaling in fructose-fed ovariectomized female Wistar rats. Eur J Nutr 2011;50:543-51.
32. Lassegue B, Griendling KK. NADPH oxidases: functions and pathologies in the vasculature. Arterioscler Thromb Vasc Biol 2010;30:653-61.
33. Fraga CG. Plant polyphenols: how to translate their in vitro antioxidant actions to in vivo conditions. IUBMB Life 2007;59:308-15.
34. Galleano M, Verstraeten SV, Oteiza PI, Fraga CG. Antioxidant actions of flavonoids: thermodynamic and kinetic analysis. Arch Biochem Biophys 2010;501:23-30.
35. Fraga CG, Galleano M, Verstraeten SV, Oteiza PI. Basic biochemical mechanisms behind the health benefits of polyphenols. Mol Aspects Med 2010;31:435-45.
36. Actis-Goretta L, Leveques A, Giuffrida F, Romanov-Michailidis F, Viton F, Barron D, et al. Elucidation of (-)-epicatechin metabolites after ingestion of chocolate by healthy humans. Free Radic Biol Med 2012;53:787-95.
37. Ottaviani JI, Momma TY, Kuhnle GK, Keen CL, Schroeter H. Structurally related (-)-epicatechin metabolites in humans: assessment using de novo chemically synthesized authentic standards. Free Radic Biol Med 2012;52:1403-12.
38. Verstraeten SV, Mackenzie GG, Oteiza PI, Fraga CG. (-)-Epicatechin and related procyanidins modulate intracellular calcium and prevent oxidation in Jurkat T cells. Free Radic Res 2008;42:864-72.
39. Mackenzie GG, Delfino JM, Keen CL, Fraga CG, Oteiza PI. Dimeric procyanidins are inhibitors of NF-kappaB-DNA binding. Biochem Pharmacol 2009;78:1252-62.
40. Fraga CG, Oteiza PI. Dietary flavonoids: role of (-)-epicatechin and related procyanidins in cell signaling. Free Radic Biol Med 2011;51:813-23.
41. Vazquez-Prieto MA, Bettaieb A, Haj FG, Fraga CG, Oteiza PI. (-)-Epicatechin prevents TNFalpha-induced activation of signaling cascades involved in inflammation and insulin sensitivity in 3T3-L1 adipocytes. Arch Biochem Biophys 2012;527:113-8.
42. Bedard K, Krause KH. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev 2007;87:245-313.
43. Piotrkowski B, Calabró V, Galleano M, Fraga CG. (-)-Epicatechin prevents alterations in the metabolism of superoxide anion and nitric oxide in the hearts of l-NAME-treated rats. Food Funct 2015;6:155-61.
44. Costa MA, Elesgaray R, Caniffi C, Fellet A, Mac Laughlin M, Arranz C. Role of nitric oxide as a key mediator on cardiovascular actions of atrial natriuretic peptide in spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 2010;298: H778-86.
45. Chen CA, Druhan LJ, Varadharaj S, Chen YR, Zweier JL. Phosphorylation of endothelial nitric-oxide synthase regulates superoxide generation from the enzyme. J Biol Chem 2008;283:27038-47.
46. Ramirez-Sanchez I, Maya L, Ceballos G, Villarreal F. (-)-Epicatechin induces calcium and translocation independent eNOS activation in arterial endothelial cells. Am J Physiol Cell Physiol 2011;300:C880-7.
47. Garcia-Cardena G, Martasek P, Masters BS, Skidd PM, Couet J, Li S, et al. Dissecting the interaction between nitric oxide synthase (NOS) and caveolin. Functional significance of the nos caveolin binding domain in vivo. J Biol Chem 1997;272: 25437-40.
48. Lobysheva I, Rath G, Sekkali B, Bouzin C, Feron O, Gallez B, et al. Moderate caveolin-1 downregulation prevents NADPH oxidase-dependent endothelial nitric oxide synthase uncoupling by angiotensin II in endothelial cells. Arterioscler Thromb Vasc Biol 2011;31:2098-105.
49. Ding H, Hashem M, Triggle C. Increased oxidative stress in the streptozotocininduced diabetic apoE-deficient mouse: changes in expression of NADPH oxidase subunits and eNOS. Eur J Pharmacol 2007;561:121-8.
50. Ginnan R, Jourd'heuil FL, Guikema B, Simons M, Singer HA, Jourd'heuil D. NADPH oxidase 4 is required for interleukin-1beta-mediated activation of protein kinase Cdelta and downstream activation of c-jun N-terminal kinase signaling in smooth muscle. Free Radic Biol Med 2013;54:125-34.
51. Kelley GL, Allan G, Azhar S. High dietary fructose induces a hepatic stress response resulting in cholesterol and lipid dysregulation. Endocrinology 2004; 145:548-55.
52. Giani JF, Mayer MA, Munoz MC, Silberman EA, Hocht C, Taira CA, et al. Chronic infusion of angiotensin-(1-7) improves insulin resistance and hypertension induced by a high-fructose diet in rats. Am J Physiol Endocrinol Metab 2009;296: E262-71.
53. Touyz RM, Yao G, Viel E, Amiri F, Schiffrin EL. Angiotensin II and endothelin-1 regulate MAP kinases through different redox-dependent mechanisms in human vascular smooth muscle cells. J Hypertens 2004;22:1141-9.
54. Yoshizumi M, Abe J, Haendeler J, Huang Q, Berk BC. Src and Cas mediate JNK activation but not ERK1/2 and p38 kinases by reactive oxygen species. J Biol Chem 2000;275:11706-12.
55. Go YM, Patel RP, Maland MC, Park H, Beckman JS, Darley-Usmar VM, et al. Evidence for peroxynitrite as a signaling molecule in flow-dependent activation of c-Jun NH(2)-terminal kinase. Am J Physiol 1999;277:H1647-53.
56. Viedt C, Soto U, Krieger-Brauer HI, Fei J, Elsing C, Kubler W, et al. Differential activation of mitogen-activated protein kinases in smooth muscle cells by angiotensin II: involvement of p22phox and reactive oxygen species. Arterioscler Thromb Vasc Biol 2000;20:940-8.
57. VogiatzoglouA, MulliganAA, LubenRN, LentjesMA, HeissC, KelmM, et al. Assessment of the dietary intake of total flavan-3-ols, monomeric flavan-3-ols, proanthocyanidins and theaflavins in the European Union. Br J Nutr 2014;111:1463-73.
58. Knaze V, Zamora-Ros R, Luján-Barroso L, Romieu I, Scalbert A, Slimani N, et al. Intake estimation of total and individual flavan-3-ols, proanthocyanidins and theaflavins, their food sources and determinants in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Br J Nutr 2012;108:1095-108.